In the context of mesothelin-redirected CAR-T therapy for ovarian cancer, a recent study by Liang and colleagues attempted to address this issue through the development of tandem CAR-Ts that target FOLR1 (by the means of the MOv19 scFv) and mesothelin (by the means of the P4 scFv) while engineered to secrete IL-12 for supportive immunomodulatory effects (147). Here, MSLN is linked to ovarian cancer.